Abstract
There is evidence that increased intake of fish oil, rich in long-chain n-3 polyunsaturated fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may beneficially affect the development and course of multiple sclerosis. However, controlled trials have not been able to draw definitive conclusions. The conflicting results could be due to the different mixture of EPA and DHA present in different sources of fish oils used in the clinical trials. In fact, among n-3 polyunsaturated fatty acids, EPA has the most potent effect on myelinogenesis and inflammatory process. The purpose of this chapter is to review the current knowledge on mechanisms underlying these beneficial effects and the evidence of neurological benefits of EPA, looking specifically at multiple sclerosis.
| Original language | English |
|---|---|
| Title of host publication | Nutrition and Lifestyle in Neurological Autoimmune Diseases |
| Subtitle of host publication | Multiple Sclerosis |
| Publisher | Elsevier Inc. |
| Pages | 267-273 |
| Number of pages | 7 |
| ISBN (Electronic) | 9780128054444 |
| ISBN (Print) | 9780128052983 |
| DOIs | |
| Publication status | Published - Jan 18 2017 |
Fingerprint
Keywords
- Docosahexaenoic acid
- Eicosapentaenoic acid
- Fish oil
- Multiple sclerosis
- Myelin repair
- N-3 Polyunsaturated fatty acids
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
Eicosapentaenoic Acid in Myelinogenesis : Prospective in Multiple Sclerosis Treatment. / Di Biase, A.; Attorri, L.; Di Benedetto, R.; Salvati, S.
Nutrition and Lifestyle in Neurological Autoimmune Diseases: Multiple Sclerosis. Elsevier Inc., 2017. p. 267-273.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Eicosapentaenoic Acid in Myelinogenesis
T2 - Prospective in Multiple Sclerosis Treatment
AU - Di Biase, A.
AU - Attorri, L.
AU - Di Benedetto, R.
AU - Salvati, S.
PY - 2017/1/18
Y1 - 2017/1/18
N2 - There is evidence that increased intake of fish oil, rich in long-chain n-3 polyunsaturated fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may beneficially affect the development and course of multiple sclerosis. However, controlled trials have not been able to draw definitive conclusions. The conflicting results could be due to the different mixture of EPA and DHA present in different sources of fish oils used in the clinical trials. In fact, among n-3 polyunsaturated fatty acids, EPA has the most potent effect on myelinogenesis and inflammatory process. The purpose of this chapter is to review the current knowledge on mechanisms underlying these beneficial effects and the evidence of neurological benefits of EPA, looking specifically at multiple sclerosis.
AB - There is evidence that increased intake of fish oil, rich in long-chain n-3 polyunsaturated fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may beneficially affect the development and course of multiple sclerosis. However, controlled trials have not been able to draw definitive conclusions. The conflicting results could be due to the different mixture of EPA and DHA present in different sources of fish oils used in the clinical trials. In fact, among n-3 polyunsaturated fatty acids, EPA has the most potent effect on myelinogenesis and inflammatory process. The purpose of this chapter is to review the current knowledge on mechanisms underlying these beneficial effects and the evidence of neurological benefits of EPA, looking specifically at multiple sclerosis.
KW - Docosahexaenoic acid
KW - Eicosapentaenoic acid
KW - Fish oil
KW - Multiple sclerosis
KW - Myelin repair
KW - N-3 Polyunsaturated fatty acids
UR - http://www.scopus.com/inward/record.url?scp=85024398486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024398486&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-805298-3.00027-X
DO - 10.1016/B978-0-12-805298-3.00027-X
M3 - Chapter
AN - SCOPUS:85024398486
SN - 9780128052983
SP - 267
EP - 273
BT - Nutrition and Lifestyle in Neurological Autoimmune Diseases
PB - Elsevier Inc.
ER -